reason report
bottom line publish individu one-pag compani
preview cardio ew nvcn
large-cap diversifi diabetes/oth avdr
necessarili specif remain large-
cap mid-cap small-cap given prefer
revenu growth acceler margin expans strong product
cycl upward estim revis potenti prospect
quarter expect seem reason
quarter vs past also feel like -- particularli cardio
hospit util survey link predict broader
trend -- upsid might limit recent quarter
context highlight stock high
convict upsid quarter fy guidanc share
appreci print -- op op
see highest potenti beat rais
likelihood share upsid print
compani high convict potenti
quarterli beat either top bottom-lin may rais
guidanc enough and/or issu ahead consensu
guidanc could limit share upsid includ
compani see risk print includ ew --
believ could fail deliv elev investor expect
 tavr -- believ bracket consensu
medic suppli devic
compani inform svb leerink llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
sale ep guidanc could disappoint quarterli
compani coverag univers either expect
larg in-lin print reason expect like caus
stock trade sideway and/or stock reaction larg
predic clinic updat includ
svb leerink estim factset
quarter expect deliv solid sale beat base season
sequenti growth trend histor intern busi impella sale
q/q histor ramp contribut japan sale growth step
rang ytd come toughest y/i comp last year us way signal
slow momentum contrari continu believ deliv strong double-digit growth patient
utilization/util per center particularli cardiogen shock initi roll nationwid center
late januari high-risk pci awar build regardless think guidanc key
driver share print attribut least stock recent weak mid-teen
last week buysid expect below-street guid expect conserv
first issuanc guidanc believ compani like guid sale growth
midpoint rang us consensu -- oper margin could
pressur share increment wed note share weak like mitig
fact below-consensu sale guid alreadi seem least somewhat reflect stock
abmd tendenc guid conserv initi compani rais
guidanc everi quarter ultim beat initi guidanc like least
wed recommend buy guidance-rel weak beyond print
guid investor focu time stemi pivot trial start global healthcar confer late
februari note final fda approv letter immin competit landscap
paus php pivot trial potenti impact possibl reimburs chang come ipp
propos possibl print impact rp dear letter new product like impella connect
recent note -- flash takeaway svb leerink global healthcar confer
outperform -- flash takeaway svb leerink global healthcar confer
quarter expect deliv basic in-lin sale despit ramp fx headwind help
potenti out-performance across key product line includ mitraclip structur heart alin lab
diagnost libr diabet well electrophysiolog overal off-set possibl continu weak
rhythm manag new major product launch diagnost tough y/i compar driven
flu season establish product think expect high base season trend
given believ like basic in-lin sale perform need deliv
meaning oper margin out-performance weve seen last quarter and/or
opex line benefit possibl tax rate hedg gains/loss order beat ep us
consensu continu drive posit oper synergi acquisit st jude
aler dont high level convict beat come oper margin also inclin
think could leav guidanc organ sale growth ep
unchang even earlier-than-expect march approv expand mitraclip indic
like cite need secur reimburs reason remain conserv believ
ep beat like driven non-oper expens guidanc unlik chang dont
view earn posit catalyst share could even downsid risk
earn
resultsactualestimatey/i growthconsensusvariancetot good gross gener administr develop ep metricstot impella custom patient treat per breakdownu impella impella impella non-impella compani report factset consensu visibl alpha consensu svb leerink resultsactualestimatey/i growthconsensusvariancenet good gener administr develop ep region total segment total cardiovascular establish pharmaceut diabet compani report svb leerink estim factset visibl inc outperform price
quarter expect deliv modest sale beat rang vs us
consensu histor season trend hold atriclip like area
out-performance continu atriclip momentum support increas awar
around benefit close laa left atrial appendag also on-going roll-out new premium-
price product like flex deliv sale closer would repres
y/i growth high end manag guidanc rang year given
repres atrc easiest y/i comp inclin think manag err side
conservat reiter sale guidanc said ultim think deliv
sale growth high end rang believ upsid like chang guidelin
open ablat busi support continu growth particularli cabg largest least
penetr market new product increas awar continu atriclip adopt momentum
china come back on-line re-ramp year progress new distributor board note
recogn basic sale china compani doesnt break china
specif asia repres almost total sale possibl even import stock
reaction earn guidanc updat around impact open ablat busi
recent low-risk tavr transcathet aortic valv replac data pressur surgic aortic valv
volum wed note howev atrial fibril diagnosi often key decid factor send patient
surgeri vs tavr insul atrc busi increment commentari time
converg pivot trial readout manag isnt like meaning updat follow-up
wont complet septemb submiss like month follow expect manag
address rational behind wait releas data conjunct expect fda panel
meet like
recent note top pick outlook
quarter expect avdr least come line revenu estim
y/i q/q potenti upsid driven improv util new exist account
major growth possibl out-performance like driven specif within
 higher drug revenu avdr focus increas util account vs ad new
center though expect new center ad manag project
product-specif j-code place januari foundat place reimburs
perspect drive increas util regard guidanc inclin think
manag exercis prudent conservat given limit histori publicli trade
compani leav guidanc y/i midpoint unchang outsid
earn guidanc expect manag discuss anecdot commentari around impact
j-code clearli posit reimburs perspect manag note expect
disrupt initi expect hear whether fact see could sourc
upsid rel guidanc clinic updat specif epi-on enrol progress
enrol year-end time phase iia presbyopia data last updat year-end
potenti updat come ascr american societi cataract refract surgeri meet
earli may overal given expect modest beat guidanc reiter dont
necessarili believ earn meaning catalyst though consecut
sale beat could start build investor confid
recent note avdr top-tier growth under-penetrated market clearli kxl
 initi outperform
resultsactualestimatey/i growthconsensusvariancetot develop gener administr incom breakdownu devic drug devic drug avedro compani report factset consensu svb leerink resultsactualestimatey/i growthconsensusvariancetot product gener administr develop incom ep region breakdownopen-heart ablat ablat tool compani report factset consensu visibl alpha consensu svb leerink baxter inc outperform price
quarter expect deliv modest sale upsid low-single-digit rang anywher
vs consensu lead even dramat ep beat expect
ep guidanc rais base back-of-the-envelop analysi sale growth trend see potenti upsid
pharmaceut even impact brevibloc cyclo advanc surgeri pharma especi
gener repres higher margin busi rel corpor averag expect could drive
meaning margin out-performance vs us consensu medic deliveri probabl
import line item given investor concern compani abil ramp achiev
oper organ sale growth guidanc medic deliveri think
estim may prove bit high given tough comp y/i repres headwind accord manag
think consensu reason achiev given recent stabl trend
busi accord manag commentari intra-quart well believ increas visibl
busi thu forecast high level convict abl reiter
medic deliveri sale growth guidanc provid commentari point continu improv trend
us repres one higher convict beat rais compani head earn
within coverag univers even share ytd think solid beat rais
along posit commentari medic deliveri trend reassur sale growth
guidanc achiev share trade higher
quarter expect bsx revenu come basic line us y/i report
y/i oper consensu mayb margin better driven possibl upsid
peripher intervent pi medsurg busi ep perspect expect drive oper
leverag favor product mix potenti bring ep manag guidanc rang
least high end rang given limit sale upsid quarter dont anticip
guidanc rais current organ sale growth ep earli year
could limit posit share upsid given though expect organ sale growth fall well within
guidanc rang quarter full year actual think investor expect
meaning beat quarter somewhat low rather think lot share perform earn
manag commentari key new/upcom product launch eluvia alreadi launch
pi lotu roll europ slate approv earli structur heart ranger dcb
avail europ expect secur approv pi eluvia ranger fda dear
doctor letter like effect remov sale go forward could alter bsx strategi ranger longer term
lotu recent low-risk data two competit valv seem least alter view lotu
competit posit among investor expect manag lower sale growth ep
guidanc issu believ manag could address ask think
effect removal/limit would key sourc upsid near-to-medium
term beat rais stori past still believ bsx top-tier sale growth profil
sustain regardless due divers portfolio weak share repres
opportun one compel sustain top-tier growth compani large-cap med-tech
resultsactualestimatey/i growthconsensusvariancenet good gener administr develop incom ep region total product total rhythm compani report factset consensu visibl alpha consensu svb leerink resultsactualestimatey/i growthconsensusvariancenet good gener administr develop ep region total baxter baxter product renal therapi deliveri surgeri baxter compani report factset consensu visibl alpha consensu svb leerink cardiovascular system inc outperform price
quarter expect deliv modest beat base histor season trend
busi abl deliv revenu rang slightli estim
y/i consensu would repres consecut quarter low-
double-digit sale growth like growth acceler stack comp basi reinforc
investor view manag drive growth acceler support stabl growth
core peripher coronari busi supplement new revenu stream intern
ancillari product like balloon guidewir still modest beat wouldnt expect
manag rais sale guidanc y/i guidanc impli
y/i growth back half year stock nearli ytd dont
see increment upsid share print without beat guidanc rais beyond quarter
guidanc investor like focu manag commentari around potenti impact
paclitaxel meta-data analysi publish jaha fda dear doctor letter whether either
acceler atherectomi adopt volum dcb drug-coat balloon declin disrupt
referr pattern actual drove fewer peripher intervent procedur overal tend believ
anyth paclitaxel nois could net-posit atherectomi whole also acknowledg
could take time play overal continu believ repres sustain double-
digit growth stori improv execut given believ compani signific competit
advantag calcifi below-the-kne lesion within peripher well grow market-
lead posit highli under-penetrated coronari market
recent note ghcc takeaway
quarter expect deliv anoth strong beat quarter sale potenti
come ahead slightli below-consensu estim y/i vs
consensu quarter think magnitud beat could fall slightli
averag saw key differ year price headwind
model sensor price per day vs exit compar
believ lower-cost competit product stand per day despit price headwind
expect continu outperform new patient add driven strong adopt momentum
increas awar around cgm continu glucos monitor therapi overal even strong
sale beat actual dont high convict manag rais sale guidanc
given price headwind materi
reflect manag initi guidanc uncertainti around competit
launch time on-going roll-out ultim though expect dramat exceed
guidanc us street y/i continu build
adopt momentum like off-set price regardless even share
recent high think investor hesit get involv ahead abt mp
libr launch expect potenti libr secur icgm statu
view like clear event think could mitig potenti share move
resultsactualestimatey/i growthconsensusvariancetot good gross gener administr develop ep region total breakdown total sensor durabl compani report svb leerink estim factset visibl resultsactualestimatey/i growthconsensusvariancetot product gener administr develop incom ep metricstot pad devic cad devic breakdownpad devic devic product compani report factset consensu visibl alpha consensu svb leerink edward lifesci corp ew market perform price
quarter expect ew recent medacorp tavr tran cathet aortic valv replac
survey impli best in-lin thv quarter vs consensu y/i q/q fall bit
consensu estim y/i q/q tavr market model assum
volum growth sequenti point market share shift favor mp compar survey
project flat q/q volum growth ew cede point market share
could impli upsid below-consensu estim upsid aggress consensu estim seem
unlik view look global tavr expect quarter expect eu off-set
potenti weak given recent share loss ew roll ultra center manag note
initi launch control wed expect littl increment impact quarter focu like
current ew center cannib exist sapien volum beyond tavr think ew could drive
upsid consensu surgic heart valv critic recent season trend hold despit
think manag like maintain sale guidanc ep guidanc
tavr sale growth guidanc given earli year without meaning upsid
tavr low risk timing/adopt curv still somewhat uncertain manag team like err side
caution could view neg street though think conserv stanc larg expect
ew still near post-acc high mid-march year-to-d major catalyst
expect year low risk data behind us see downsid risk upsid potenti
 tavr sale miss even fail beat next quarter still maintain mp
rate believ investor like give ew pass quarter due time low risk data
week end march move howev believ ew return
consist beat rais tavr specif tavr share work remain
cautiou near-term low risk ramp street
recent note tavr survey live wrap-up
quarter expect come below-consensu estim y/i
line street base recent trend inclin think abl drive upsid
dtc busi back-of-the-envelop math suggest compani could drive upsid
assum recent rep product trend hold albeit dilut new rep ad
mani yet fulli product intern last year season trend would point
signific upsid current estim though expect low-single-digit upsid dollar
basi given consist histor season trend rel lumpi busi protract
weak domest busi like mitig total sale upsid rel consensu wed
expect sale come line even slightli current estim believ
ultim net basic in-lin print vs consensu would expect manag reiter
sale guidanc growth acceler vs comp eas rep
add continu ramp share pull back meaning last month nearli
high wed expect littl stock movement quarter without beat rais
sens expect particularli high also dont think need
continu trend consist beat rais get stock move beyond quarterli
result guidanc believ investor focu potenti top bottom-lin impact just-
announc launch manag previous said reflect guidanc
increment feedback major nation provid aggress slow purchas
potenti time ramp purchas competit dynam nr roll mobi poc
resultsactualestimatey/i growthconsensusvariancetot develop market administr incom ep domest domest direct sale compani report svb leerink estim resultsactualestimatey/i growthconsensusvariancenet gener administr develop continu ep region domest product tavr corevalv tavr tavr transcathet aortic valv surgic heart valv critic transcathet mitral tricuspid ew compani report svb leerink estim factset visibl corpor outperform price
quarter expect deliv modest upsid vs us y/i
consensu upper half sale guidanc rang
expect beat new patient add project driven larg shift
pharmaci current busi late februari well on-going dash
roll-out broader roll-out begun quarter expect absorb
headwind elimin person diabet manag revenu like mitig
upsid potenti omnipod revenu though think small beat possibl
intern expect abl deliv meaning beat rang
histor season patient add trend hold accord model particularli
sell direct intern given uncertainti around time new patient
start pharmaci channel continu establish market access think
manag could leav sale guidanc unchang
y/i relat stock buysid expect seem reason low us
feel us mere need success execut next quarter
deliv result line modestli better guidanc estim
key new growth driver hit potenti drive growth reacceler type year-end
horizon artifici pancrea even share nearli ytd
manag deliv in-lin slightli better result issu posit commentari around
patient demand intern well strong execut around
shift pharmaci think share could move higher still print ultim
view one cleanest execut stori within smid-cap coverag univers
ramp adopt still larg under-penetrated pump market primari market
grower given highli differenti wearabl footprint like drive sustain double-digit
growth forese futur
quarter expect kick med-tech earn season like set investor
expect quarter relat procedur volum trend overal base
medacorp hospit administr survey look basic stabl reflect expect modest
seasonally-driven step-down vs specif expect see modest upsid
estim vs consensu believ consum
continu turn around medic devic growth continu see modest growth
reacceler pharma drive lion share out-performance like
continu adopt ramp new core drug includ tremfya darzalex well
simponi stelara given move part includ gener competit zytiga
think manag reiter current guidanc organ growth ep
believ print investor focu chang
manag view abil deliv pharma growth zytiga gener headwind
repres first full quarter gener competit could help inform go-forward outlook bit
wholli success recent/upcom launch medic devic manag
larg reli return busi within broader market growth quarter
project stabl slightli improv organ growth vs updat talc liabil
chang manag view around risk tie on-going litig appetit
recent note -- ghcc takeaway robot readthrough follow acquisit auri
resultsactualestimatey/i growthconsensusvariancetot good gross gener administr develop incom cont ep overviewtot us omnipod omnipod deliveri revenu compani report factset consensu first order analyt svb leerink plc market perform price
quarter expect beat modestli sale like cardiovascular group cvg
weak slower dcb growth tie paclitaxel fda dear doctor letter continu lvad left
ventricular assist devic weak off-set mitg rtg strength histor season
trend hold dont high level confid mdt abil deliv upsid margin
thu ep beat like come non-oper expens even importantli
howev issu guidanc post-earn call expect recent
cvg headwind persist diabet growth deceler meaning given product
cycl would expect manag guid organ sale growth closer vs
base manag commentari start year expect
ep growth below-trend long-term growth guidanc driven
higher tax rate fx headwind margin wed expect guid ep around
midpoint like captur consensu high end rang
think share risk print though share rel
underperform ytd still think big driver mdt multipl discount inconsist
beat even deliv expect dont think quarter
reinforc investor confid meaning expect focu earn call
abil drive sale growth acceler long-term eventu return growth in-lin
med-tech market sustain mid-single-digit potenti impact paclitaxel meta-data
analysi mdt pact admir dcb mid-teen global grower market share
leader appetit increment
recent note investor dinner note
quarter expect nvcn focu tiara clinic progress financi health
compani cash bank legal overhang remov still
compani cash posit like sustain develop less year point
manag hope posit reduc grow and/or partner tiara
much closer market nvcn recent report total number tiara implant reach
march vs novemb august may march believ
manag provid updat clinic trial progress tiara hope see
acceler enrol clariti potenti time tiara trial complet
cash hand decemb two equiti rais total gross
think nvcn cash posit suffici fund oper next month
relat stock around print progress clinic develop key
expect manag convey progress ultim view nvcn front-runn
commerci tmvr transcathet mitral valv replac devic multi-billion
market possibl peak much leerink estim litig
settl compani need provid anoth fundrais plan remov
financi overhang investor clariti nvcn continu oper believ
nvcn share move meaning higher appropri reflect long-term
recent note ghcc takeaway
resultsactualestimatey/i growthtot good gross gener administr develop ep compani report svb leerink result million actualestimatey/i growthconsensusvariancenet good gener administr develop ep region total product cardiac vascular group therapi group mitg therapi group compani report factset consensu visibl alpha consensu svb leerink corp outperform price
million
quarter expect potenti upsid revenu estim
y/i consensu like driven slightli better market growth
model anoth meaning step spinal cord stimul market growth
quarter flat-to-slightli dollar basi vs despit fact major
industri player reiter view remain growth market also model
point sequenti share loss seem reason us given recent rep
turnov issu seem larg stabil toward end relat
since-withdrawn sale growth guidanc find hard imagin newly-appoint
ceo keith grossman join mid-march would actual reissu lower guidanc though
also sens investor think possibl mayb even like tend believ grossman
reissu sale growth guidanc guidanc impli signific
 share loss despit believ stabl salesforc fact market
grow acknowledg increment risk ou side
relat recent australian reimburs chang like repres less
total sale ultim though relat stock almost feel quarter
doesnt matter earn call repres first time investor hear
grossman he learn busi plan ultim turn
sustain share-gain double-digit grower stock sinc
low reach late last year think grossman commentari call could
drive upsid support share ultim think exceed
expect year like grow least in-lin market execut improv
recent note new ceo appoint
quarter expect come basic in-lin estim factset
consensu driven primarili on-going eversens adopt momentum europ
potenti modest upsid launch key share perform view
anecdot commentari around on-going germani launch increment launch commentari
eu countri importantli launch eversens start
key gate factor block tackl around reimburs secur
coverag secur cover live note eversens secur new patient
add across rang patient type europ -- experienc libr user
former user remain type new cgm continu glucos
monitor therapi strong adopt momentum libr bode well
eversens benefit libr expand market captur exist libr patient prefer
conveni long-wear sensor view addit senss patient access bridg program
could grow instal base rapidli make technolog afford patient
reject reimburs roch distribut agreement resign visibl
price expect manag reiter sale guidanc
particularli given back-end load natur ramp relat stock think
move almost entir predic manag commentari around anecdot evid
support bullish view adopt momentum improv reimburs ultim
believ verg dramat sale inflect point on-going launch
eversens implant cgm continu glucos monitor believ nearli
total address market alon
dollar thousand except per share amount
resultsactualestimatey/i growthconsensusvariancetot good gross gener administr develop ep metricsend us breakdowndomest compani report factset consensu visibl alpha consensu svb leerink resultsactualestimatey/i growthtot good gross gener administr develop ep compani report svb leerink vericel corpor outperform price
quarter expect deliv meaning upsid current estim
y/i street driven ramp maci adopt trend compani
continu train surgeon util new exist center continu ramp
despit face tough comp model current assum exit train
surgeon includ new surgeon train quarter vs train per quarter
util procedur per surgeon vs estim us leav plenti
room upsid base recent season trend think drive maci sale closer
vs estim epicel estim could touch high
model modest sequenti growth vs low-single-digit declin q/q last year lumpi
busi highli unpredict real histor trend follow ultim even epicel
come bit light think make shortfal maci
given view current guidanc y/i y/i conserv
easili beatabl inclin think manag like rais guidanc
least beat relat stock interestingli recent investor feedback would
suggest concern estim high someth obvious disagre
share nearli recent high like due concern
think setup quarter favor expect deliv gross
margin vs compani drive leverag ramp volum
recent note manag meet ghcc takeaway
rate share outperform price target believ abiom
manufactur impella famili percutan ventricular assist devic pvad well-
posit deliv sustain strong double-digit sale growth near-to-midterm
time-frame project sale compound-annual-growth-rate
compani drive increas penetr prophylact high-risk percutan
coronari intervent pci cardiogen shock patient popul estim nearli
patient treat abiom impella impella cp
pci perform annual base medacorp physician
convers anywher pci could consid high-risk
would benefit impella anoth pci cardiogen shock patient
compani benefit new product higher flow impella cp receiv pma approv
 april indic shock new geographi notabl
japan receiv approv octob launch impella
addit receiv fda approv impella rp right heart failur
compani continu add new center
center total ad center per quarter
us biggest barrier impella adopt awar impella
pma-approv protect pci impella devic includ higher flow impella
cp approv cardiogen shock aggress market train
hospit heart team util broad clinic dataset train capabl impella
six clinic guidelin drive awar help guid clinic
practic eas patient select
even adopt inflect upon protect pci pma approv late believ
impella adopt pois ramp given
highli under-penetrated market opportun within protect pci cardiogen shock
impella today penetr
concert effort among physician rais awar around treat grow
number complex patient pci procedur volum patient grow
mid-single-digit rang base estim
pma approv protect pci cardiogen shock allow
aggress market impella use broad clinic dataset support safeti efficaci
cost-effect well train clinician nurs
indic geograph expans on-going launch impella rp
patient opportun on-going launch japan current
patient balloon pump patient extracorpor membran
oxygen ecmo repres low-hang fruit impella view
oper margin expans stori believ abiom drive on-going posit oper
leverag primarili within sg ultim push oper margin
next month believ share
move higher current level compani continu deliv consist quarterli sale
beat push oper margin higher
price target appli ev/sal multipl estim
assum stabl multipl vs current estim continu believ
top-tier sale growth profil profit warrant premium repres uniqu
asset increasingli volatil market
risk rate valuat includ failur drive increas util rate
and/or continu add new account steadi rate failur execut pipelin
launch new geographi potenti reimburs declin potenti competit
pvad product secur approv gain meaning market share potenti
rate share market perform price target abbott
like path top-lin growth acceler compani like reinvest
busi complet integr acquisit includ alr stj
deal potenti bolster compani sale ep growth outlook
becom formid player med-tech diagnost even broader offer
believ margin expans continu remain key piec abbott long-term invest
thesi abbott also attract investor look safer defens stock
healthi dividend yield current increasingli volatil market
help sustain current multipl abbott succeed drive meaning margin expans
nutrit busi margin mid-teen level post-split still
go increas cost effici suppli chain manufactur
abbott pipelin also number smaller increment new product launch expect
next year beyond pend acquisit xienc stori
larg play estim basic stabl drug elut stent market share next
year view abbott like less acquisit immedi term follow
two larg acquisit remain sidelin given valuat rel still-high
expect uncertainti potenti sale upside/increment margin expans
expect share trade assum multipl ep
estim modest discount large-cap med-tech group
clearli pois drive above-market sale growth next year believ
current valuat alreadi reflect high convict consist
beat rais stori potenti execut risk around new product launch --
heavili depend notabl freestyl libr mri-saf high power devic -- see
opportun potenti downsid vs meaning clear-cut upsid
risk includ potenti slow end-market growth and/or increas competit
major product includ abbott xienc de total current abbott sale product
recal manufactur warn letter could push oper cost higher hinder sale
growth success pipelin execut key abbott growth stori product
approv time approv becom increasingli uncertain today challeng
regulatori environ success execut margin expans opportun
environ increas price pressur potenti acquisit could dilut
rate share outperform price target
believ well-posit sustain double-digit top-lin growth least
next year compani core open ablat busi -- make
sale -- well-posit deliv sustain mid-single-digit growth forese futur
penetr ramp beyond guidelin chang acceler
continu advanc mi minim invas ablat pipelin could ultim
open multibillion-dollar atrial fibril af ablat market opportun address
atrial fibril patient
ceo carrel appear commit compani current long-term growth strategi
penetr concomit open heart surgic ablat market expand mi surgic
ablat drive atriclip sale cross-sel expand intern
near term manag work ensur limited-to-no sale forc disrupt compani
continu focu penetr leerink estim global concomit surgic
ablat market -- less penetr today compani success advanc
clinic trial initi converg frost deep progress
next month believ share trade valuat appli
ev/sal multipl revenu estim assum basic stabl multipl
current level estim compani get back track deliv
consist out-performance street estim move higher current level believ
share deserv least maintain slight discount broader small-cap med-tech
univers averag includ believ
compani continu deliv given stabl mid-to-high teen sale growth outlook
longer term mi come line potenti meaning sale oper synergi
estech ncontact acquisit close increasingli clear pathway
profit turn ebitda posit base estim
risk includ failur success execut surgeon train new af indic
adopt concomit surgic ablat clinic trial delay failur receiv
clearanc next gen atriclip system ou regulatori delay ncontact
rate avdr share outperform rate price target us avedro repres
top-tier smid-cap growth compani clear pathway profit current project
sale compound-annual-growth-rate sustain net profit key growth
driver commerci kxl cross-link system photrexa treat
keratoconu progress corneal disord estim repres least
market opportun base case underway sinc septemb reimburs
significantli much better cover adopt ramp acceler
longer term believ reason potenti estim upsid and/or tam
expans keratoconu still meaning underdiagnos improv diagnost tool
increas awar around minim invas treatment option slow diseas
progress kxl cross-link system believ diagnos thu referr could
acceler push closer bull case scenario beyond
exist indic avedro also pursu expand indic vision correct
notabl potenti presbyopia market opportun given earli
regulatori timelin phase trial begin ex view potenti market
expans call option presbyopia current exclud estim
dcf analysis/valu
next month believ avdr share trade arriv valuat
use discount cash flow dcf compar compani ev/sal analysi dcf
arriv valuat compar compani analysi arriv
valuat rang valuat appli ev/sal multipl
sale estim current avdr share trade
estim sale estim discount compar
higher-growth small-cap med-tech group consist nr nr
nr nr current trade
averag sale estim sale estim believ
fundament support valuat ev/sal rang assum discount
due avdr execut risk tie on-going commerci kxl
manag build track record first quarter public compani
risk valuat includ competit entri regulatori risk associ
indic expans reimburs uncertainti
rate share outperform price target continu transit
post baxalta spin compani start see sale margin
benefit revamp pipelin believ increment margin upsid potenti
alreadi price believ magnitud sale growth reacceler potenti free
cash flow gener still underappreci level increasingli becom
strong free cash flow gener stori free cash flow target
vs potenti upsid free cash flow view increas
financi flexibl invest busi drive even faster sale growth acceler
invest inorgan outsid opportun supplement top- bottom-lin growth
given compani solid execut to-dat steadi stream upcom new product launch
addit clari fill gener inject busi increasingli confid
continu drive upsid recent updat long-term growth margin
target believ margin expans stori alreadi least partli price
stock manag current guid oper margin
see room upsid margin ramp believ major upsid
alreadi price share level
sale perspect also see potenti upsid current top-lin growth target
compound-annual-growth-rate time-frame driven new product launch geograph
expans someth feel underappreci street pipelin biggest
driver sale growth acceler next five year expect launch
new product new product expect make total sale
ramp expect signific growth pd periton dialysi gener
inject biosurgeri core growth contributor drive top line grow
solid mid-singl digit higher
overal find bax margin expans stori compel believ investor
underappreci bax sale growth reacceler stori also compani cash-
gener capabl believ ebitda repres relev
measur valu compani vs price earn combin
discount cash flow analysi ev/ebitda ev/fcf arriv price
next month believ share trade
rang dcf valuat deriv base case upsid scenario
supplement ev/fcf ev/ebitda analys pt reflect
ebitda -- premium current ebitda line
large-cap med-tech group averag valuat also fall within rang dcf
valuat deriv base case upsid scenario supplement ev/fcf
analysi estim price-to-earnings perspect pt impli multipl
ep estim repres multipl expans current level pe
ep think feasibl get back track deliv
consist beat rais
risk includ failur execut margin expans initi new product launch delay
possibl acquisit either dilut perceiv further baxter growth goal
could pressur stock
rate share outperform price target turnaround stori
well underway new manag deliv solid execut near- long-
term sale ep growth target build foundat sustain top-tier sale growth
within large-cap med-tech univers given compani recent consist deliv
ep line better expect upcom slew new product launch
increasingli confid well track achiev long-term goal laid
june analyst meet includ achiev organ sale growth
compound-annual-growth-rate -- faster broader med-tech market mid-single-digit rang
deliv gross margin achiev oper
margin togeth solidli posit deliv double-digit ep growth
next year view even growth guidanc slightli
organ sale growth deliv organ sale growth alreadi
well track view achiev long-term sale growth goal manag indic
confid sustain recent pipelin commerci execut
continu roll-out sever key new product launch meaning contributor
top bottom line includ limit watchman left atrial appendag
closur devic continu roll-out exceed expect mri-saf high
power devic launch symeti close pipelin
product coupl recent launch acquir product includ american medic
system am men prostat portfolio posit increment sale
growth acceler leav potenti upsid current project sale
litig overhang larg remov pois enter
stronger balanc sheet continu believ share well-posit
out-performance compani continu deliv consist quarter solid execut
next month believ share trade deriv appli
price-to-earnings multipl cash ep estim assum stabl multipl
current price-to-earnings multipl ep slightli price-to-earnings large-cap
med-tech group broadli top-tier sale growth
profil mid-to-high singl digit rang healthier balanc sheet head
think premium multipl justifi compani continu deliv solid execut
consist meet-or-beat quarter also ramp key new product move past
litig issu see opportun multipl expans ahead
risk includ lack meaning recoveri med-tech market broadli major boston
scientif market drug-elut stent de cardio rhythm monitor
specif failur success execut key new product launch major litig
loss potenti product recal particularli within inabl suffici reduc
cost drive oper margin expans
rate inc share outperform
month price target sever solid quarter row stabl improv growth
rel new ceo place believ compani reach fundament inflect point
sever quarter under-perform due sale forc disrupt poor execut
alway view well-posit market leader peripher atherectomi
market grow sustain high-single-digit rang coronari atherectomi market
grow even faster given competit advantag calcifi lesion knee
heavili under-penetrated market within space previou cautiou view
share larg predic lack execut august announc
interim ceo scott ward would take perman continu transit make us
increasingli confid recent sale forc stabil thu improv growth trajectori
sustain near-to-medium term
longer term believ atherectomi market may posit acceler growth
advent drug coat balloon dcb particularli indic secur
knee within next year investor fear dcb competit
atherectomi devic medacorp physician check strongli suggest fact
complementari physician use atherectomi debulk prep lesion particularli
heavili calcifi sweet spot liberti still on-going
remain one compani develop substanti dataset support atherectomi
adopt highli under-penetrated market particularli sickest critic limb ischemia
patient larg untreat current lastli coronari gain like
continu aggress gain share also grow market believ reach
penetr total pci low-single-digit today
increas focu among intervent cardiologist treat complex higher risk patient
atherectomi like becom increasingli import
beyond top line csii effort control cost announc restructur march
includ reduct workforc could push compani profit faster
previous expect believ turn sustain net incom profit
current fiscal year pathway profit enabl attract broader
investor base attract new money name continu support share
price target appli ev/sal multipl sale estim
reflect basic stabl multipl vs sale multipl
sale estim smid-cap coverag univers averag
nxtm reflect new product-rel
market share potenti product recal failur dcb drive atherectomi adopt
rate inc share outperform price target
longer term view continu glucos monitor cgm market opportun
compel potenti top estim target larg grow under-tr
patient popul type diabet initi ultim move much-larg type
patient popul seem particularli well-posit within market fda
industri work dilig toward ultim goal develop artifici pancrea
essenti cgm-augment insulin pump system automat accur dose
patient new patient adopt momentumand launchingi like
sustain sale growth near medium term despit competit headwind continu
product evolut includ possibl much less-costli type product conjunct
googl partnership help drive project sale compound-annual-growth-rate period
next month believ share could trade assum
share trade ev/sal estim share current trade
sale estim premium compar smid-cap med-tech
compani nxtm believ
continu deliv estim upsid sustain ev/sal multipl current level
ultim believ share warrant least modest premium smid-cap
med-tech stock univers given substanti highli under-penetrated total
address market per estim consist upsid potenti top-tier
risk includ failur continu evolv sensor technolog includ verili product
type patient toward sensor-integr pump potenti price pressur
increas competit potenti product recal reimburs issu
rate edward lifesci nyse ew share market perform
price target edward current market leader tavr transcathet aortic
valv replac market intern continu believ tavr
repres one excit new med-tech market high-teen higher
project market compound-annual-growth-rate time-frame base estim sens
ramp less sick patient popul current intermedi risk potenti
low risk beyond might occur slower pace already-elev investor
expect continu believ intermedi risk indic repres massiv
increment market opportun estim intermedi risk doubl
address patient popul also believ ramp patient slower
saw inoper high risk given linger question around tavr durabl
longer term need seemingli intens market develop effort drive
referr particularli younger less sick portion intermedi risk patient popul
potenti increas surgeon pushback less sick patient popul
heart member ramp effort preserv surgic busi
ultim believ global tavr market exceed new indic come
on-line low risk eventu asymptomat ew guidanc given
view low risk ramp like slower seen high risk
intermedi risk patient popul near-to-medium term ew still beat
rais stori base earli read intermedi risk adopt ramp think beat
next month may smaller tougher come
last two year particularli light competit launch addit steadier intermedi
risk ramp vs step function chang growth street seem expect share current
trade earn becom increasingli difficult argu meaning
multipl expans
price target appli price-to-earnings multipl ep estim
pt assum stabl multipl current ep still
large-cap group averag also think ew market-lead posit highli
under-penetrated total address market justifi compani premium valuat
rel rest large-cap med-tech group
risk includ inflect point intermedi risk adopt ramp neg competit
clinic data and/or competit launch delay faster-than-expect low risk
asymptomat trial ramp earlier-than-expect cardiaq feasibl trial re-start
rate share outperform op price target view
differenti technolog competitor larg under-penetr fast-grow long-
term oxygen therapi ltot market manufactur market portabl oxygen
concentr poc that gener view best-in-class base efficaci size allow
superior portabl patient mobil compani also implement uniqu direct-to-
consumer- dtc sale strategi despit well-known reimburs headwind protect
profit margin still allow higher invest versu competitor
time-frame project deliv sale compound-annual-growth-rate even
absorb increment reimburs cut
poc therapi class expand within ltot given favor demograph broaden
awar earlier diagnos underli condit copd longer life
expect oxygen therapi medacorp physician survey check suggest
poc could move much ltot mid-single-digit penetr today base
appropri patient
drive continu market share gain within poc increas awar
barrier adopt poc broadli compani inogen one specif exist
includ lack awar poc inogen one potenti higher
up-front cost patient versu tradit oxygen therapi awar continu grow
compani continu invest build sale forc dtc market effort
word mouth take hold cost frequent cite issu medacorp
physician survey spoken continu technolog improv higher
patient invest therapi decis could help mitig barrier us repres
compel invest opportun med-tech investor given high-sal growth
profit profil despit alreadi well-known reimburs headwind next
month believ share could move higher current level success execut
quarter potenti deliv upsid could prove conserv estim
pt appli ev/sal multipl now-low sale estim
assum multipl expans current level sale
line smid group despit uncertainti around market growth top-
tier growth profil solid execut deliv consist beat rais
least continu support multipl
risk share includ account issu possibl greater reimburs cut
current model loss increment competit bid contract exclud
compani access new patient potenti competitor replic implement
compani dtc strategi inabl build awar drive increas penetr
poc oxygen therapi market
rate share outperform price target johnson johnson
histor repres defens stock view johnson johnson seem also
becom offens compani success gener posit momentum
reacceler growth sinc suffer sever year below-industri growth
johnson johnson weather slow med-tech util trend ramp price pressur
major pharma patent expir actelion johnson johnson seem pois
drive sustain organ mid-single-digit top-lin growth even better high-single-digit bottom-
line growth long-term help success recent new pharma product launch zytiga
imbruvica xarelto invokana continu innovation/in-licens re-launch full
over-the-counter product portfolio basic stabl seemingli improv med-tech util
trend broadli depuy/synth trend specif compani work
integr issu dividend yield strong free cash flow gener believ
share repres attract total return vehicl investor
next month believ share trade price target price
target appli price-to-earnings multipl ep estim share current trade
ep estim large-cap med-tech group rang
price target assum see multipl
expans line broader comp group compani manag top-
line headwind continu manag cost benefit actelion --
posit sustain ep out-performance view total return capabl
attract increasingli volatil stock market environ like attract fund
risk includ failur success integr actelion amo synth potenti futur
acquisit failur resolv outstand consum consent decre success
re-launch product product recal failur advanc late-stag pipelin
success launch new product protract recoveri procedur volum trend
lack real macroeconom recoveri
rate share market perform price target believ
return mid-single-digit top-lin growth trajectori eventu nearli total
sale cardiac rhythm manag spine market estim grow
low-single-digit best mdt sustain growth trajectori larg predic
recent upcom new product launch well success integr covidien
largest acquisit compani histori
ceo omar ishrak helm clearli focus control cost help off-set
on-going price pressur slow market growth broadli med-tech excis tax
name see opportun margin expans combin compani
attempt extract signific cost synergi though compani continu make progress
time extent margin improv still remain challeng increas fx pressur
despit earli sign market stabil market growth recoveri coupl
continu soft spine inclin remain sidelin share
pend clariti execut upcom new product launch help stem
market share loss spine drive market share gain busi
success deliv increment margin expans beyond cov synergi
major med-tech market broadli spine specif experienc real
price target appli price-to-earnings multipl ep estim
assum share sustain current multipl ep estim
though believ could eventu return path consist mid-
single-digit top-lin growth -- rtg big piec growth acceler -- remain
sidelin pend clariti cvg sale abil absorb/mov
past on-going headwind ramp key pipelin product surgic robot
minim invas therapi group mitg time less certain see limit multipl
expans mid-single-digit growth trajectori larg predic new
product launch sustain trend without risk
risk valuat includ continu signific spine market spine sale declin
market fail regain momentum greater-than-expect drug elut stent de market
share loss greater infus sale declin failur deliv product pipelin failur
success execut cost save initi
rate nvcn share outperform price target though still earli
develop believ neovasc verg tap dramat larg
potenti high growth transcathet mitral valv replac tmvr market tiara
technolog neovasc tiara current forefront still nascent develop
market total number implant reach patient either feasibl
compassion use mitral regurgit mr preval aortic stenosi
tmvr clearli repres massiv virtual unpenetr market opportun peg
global tmvr market opportun assum tmvr initi target function mr patient
high risk surgeri almost tripl current transcathet aortic valv
replac tavr market estim use tavr proxi clear demand
less invas transcathet therapi high valvular diseas patient mr particularli
sever mr repres highli underserv patient popul poor surgic outcom
drive surgic penetr rate less total market tiara clearli
without risk given earli stage develop medacorp physician check suggest
tiara repres highli viabl solut given anatom d-shape leaflet independ
next month believ nvcn share trade arriv price target
use discount cash flow dcf analysi take averag valuat base rang
royalti rate dcf use discount rate probability-
weight price target reflect averag believ possibl royalti rate
rang royalti pay-out conserv scenario view
acknowledg small-cap med-tech compani valu base compar compani
ev/sal multipl believ dcf best captur total address market opportun
neovasc tiara tmvr market estim potenti global
risk neovasc rate valuat includ possibl tiara and/or reduc
approv us and/or europ commerci ramp tiara and/or reduc fail
meet expect challeng fda approv pathway tiara and/or reduc
fairli robust competit landscap mr replac pipelin on-going trademark
potenti patent litig potenti reimburs risk failur obtain suffici
reimburs tiara and/or reduc secur approv
rate share outperform price target believ
midst dramat sale inflect point fda approv highli
differenti superior tradit therapi senza spinal cord
stimul system treat chronic pain current global market per
leerink estim also view differenti senza high frequenc therapi
like market growth stimul adopt predomin back pain patient larg
untreat previous due lack efficaci like acceler senza given
proven efficaci patient popul ultim see faster-grow
market increment market growth larg accru
believ deliv least high-single-digit low-double-digit
compound annual top-lin growth see potenti upsid alreadi
top-tier sale growth profil driven
rapid aggress market share gain back fda
approv senza hf -- label includ pivot trial data claim superior
dramat eu market share gain superior label place
senza-rct clinic data wide dispers public
peer-review medic journal releas data nan annual
meet decemb
potenti faster market growth aggress adopt therapi
increas sale forc ramp penetr key account beyond
next month believ share trade appli
ev/sal multipl sale estim assum stabl multipl vs
current estim discount small-cap med-tech coverag
univers ev/sal nxtm
risk share includ difficulti shift physician adopt away current
cut potenti high frequenc competit anoth major player could impact
long-term market share and/or forc enforc intellectu properti ip right
like time-consum expens effort increment reimburs cut may
pressur price longer term
rate share outperform price target next
year continu focu drive strong referr momentum increas
sale forc product greater awar deliv believ around
nearli top-lin compound-annual-growth-rate time-frame ex neighborhood diabet insulet
underw manag transit four year ago busi stabilized-
to-acceler believ long-term market opportun pump therapi unchang
penetr type patient today solid execut
continu reinvest sale forc appear pois drive sustain re-
continu rate share op pt appli ev/sal multipl
sale estim share current trade sale
estim expect multipl hold current level given believ sustain
double-digit growth next year dramat improv profit profil --
consist net incom posit believ share deserv trade premium
ev/sal multipl smid-cap med-tech coverag univers
risk includ failur success execut adopt omnipod type patient
potenti manufactur issu and/or inabl seamlessli ramp product failur
advanc pipelin artifici pancrea product failur bring success drug
deliveri partnership commerci increas competit higher us dollar
rate share outperform price target believ senseon
verg dramat sale inflect point european launch eversens
implant continu glucos monitor cgm progress even importantli
 launch believ nearli total address market alon
still today global cgm market still much earli stage adopt
increas awar improv reimburs continu technolog evolut
longer-wear implant sensor senseon eversens play key role
like continu drive rapid growth via expand patient popul eventu
aggress penetr beyond type much-larg multi-million type patient
popul view eversens appeal broad patient popul encompass
type current declin cgm option due high burden therapi
patient also type reason us posit compani dramat top-
line growth next year clear path profit
modest penetr type margin penetr insulin-depend
type believ senseon deliv compound-annual-growth-rate time-frame
ramp sale see potenti upsid
estim driven
solid launch execut supplement potenti faster sale forc add
success pipelin execut faster market entri sensor would
competit differenti gap
on-going launch eversens sensor beyond
continu roll-out eversens xl rest europ
beyond solid execut drive sale inflect expect benefit
number posit catalyst next month includ
secur dose claim eversens sensor
progress promis trial eversens xl
next month believ share trade appli ev/
sale multipl sale ev/sal sale
pt reflect confid potenti adopt trajectori given posit earli feedback
europ best-in-class mard mean absolut rel differ ramp line
better expect share trade sale premium
small-cap med-tech coverag univers trade sale ultim believ
premium warrant given top-tier growth profil
risk share includ difficulti shift physician adopt away current
tradit cgm therapi increas competit counter-detail failur build
success sale forc train physician drive adopt failur advanc
pipelin includ sensor expand indic pediatr
rate share outperform price target believ
maintain virtual monopoli highli under-penetrated articular cartilag repair market
could ultim see open-end growth longer term recently-launch maci product
repair larg cartilag defect seen sale growth acceler
mid-single-digit third-gener product
launch broadli one-of-it kind amount support clinic data
includ summit trial demonstr superior vs standard care microfractur
year carticel use first-gener product maci procedur base
 eas use faster rehabilit time increas appeal physician
orthoped surgeon special sport medicin patient physician train
util maci continu ramp believ deliv least maci sale
growth next three year mid-teen growth sustain go-forward basi
high end compar small-cap med-tech compani coverag univers
see signific opportun upsid alreadi above-street estim driven
even higher number orthoped surgeon util maci total
orthoped surgeon identifi sport medicin specialist model current
assum surgeon train exit exit
higher util new exist surgeon maci eas use benefit well
shorter rehabilit time could drive surgeon use even frequent
saw carticel current estim estim maci procedur
per surgeon per quarter project util drop slightli
continu train new surgeon
favor gross margin profil variabl cog total
well-posit significantli expand gross margin ultim achiev sustain
oper incom net profit earlier beyond also market
autolog epiderm product address sever burn market
penetr believ epicel alon sustain high-single-digit low-double-digit grower
next month believ share trade dcf arriv
month valuat compar compani analysi arriv valuat
rang valuat appli ev/sal multipl
sale estim assum current multipl estim hold
top-tier growth profil monopoli larg under-penetrated market path
profit believ share deserv trade least line ev/sal
multipl higher-growth smid-cap med-tech coverag univers
op rate
risk valuat includ inabl execut physician train drive ramp
maci adopt potenti product recalls/regulatori issu either maci epicel
competit entrant current unawar need rais addit capit
reach profit could dilut exist sharehold inabl optim
variabl cog control oper expens order drive posit leverag
dollar million except per share data
total good sold
research develop
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share amount
product sold
research develop expens
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar thousand except per share amount
sold
research develop expens
 sale
sg sale
oper expens sale
compani report svb leerink estim
dollar million except asp
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share amount
good sold
research develop expens
pre-tax incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar thousand except per share amount
product sold
research develop expens
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
product good sold
develop good sold
total good sold
research develop expens
incom loss equiti invest
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar thousand except per share amount
sale revenu
rental revenu
sold
research develop expens
 sale
 sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
total good sold
research develop expens
loss discontinu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom attribut non-controlling interest
net incom attribut
sg sale
 sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom continu oper
earn discontinu oper net tax
net incom attribut non-controlling interest
net incom attribut
sg sale
 sale
oper expens sale
revenu report
oper revenu ex fx divestitur
compani report svb leerink estim
dollar million except ep
good sold
loss foreign exchang
basic averag share million
good sold sale
sg sale ex med-tech tax
 sale
oper expens sale
good sold
basic dilut ep
compani report svb leerink estim
compani report svb leerink estim
net incom compani
accret redeem convert prefer stock
cog sale
 sale
sg sale
oper expens sale
compani report svb leerink estim
dollar million except per share data
total good sold
research develop
dollar thousand except per share data
good sold
accret redeem convert prefer stock
net loss attribut common stockhold
dilut averag share thousand
good sold sale
sg sale ex med-tech tax
devic tax sale
 sale
oper expens sale
good sold
net incom cont op
compani report svb leerink estim
dollar thousand except per share amount
sold
research develop expens
impair intang asset
increas decreas fair valu warrant
 sale
sg sale
oper expens sale
compani report svb leerink estim
